featured
Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Diabetes Care
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes
Diabetes Care 2023 Aug 09;[EPub Ahead of Print], FA Moura, DD Berg, A Bellavia, JP Dwyer, O Mosenzon, BM Scirica, SD Wiviott, DL Bhatt, I Raz, MW Feinberg, E Braunwald, DA Morrow, MS SabatineFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.